METHOD FOR PREDICTING THE PROBABILITY OF DEVELOPMENT OF PROLIFERATING UTERUS MYOMA Russian patent published in 2018 - IPC A61B5/00 G01N33/48 

FIELD: medicine.

SUBSTANCE: invention relates to the field of medicine, namely gynecology, and can be used to predict the likelihood of proliferating uterine fibroids. Immunological study is conducted. Anamnestic data is collected. Prognostic factors are determined. When collecting anamnestic data, the following is revealed: absence of childbirth, availability of abortions, surgery on the uterus, curettage of uterine cavity with concomitant adenomyosis, availability of thyroid disease in women in combination with endometrial hyperplasia, availability of atypical myoma nodes with circulatory disorders in them. Level of interleukin-6 (IL-6) and the level of alpha-2-glycoprotein (ABG) associated with pregnancy are determined in serum. Blood supply of myoma nodes is evaluated. Screening points (SP) for each factor are set. In the system “availability of abortions”, marker “available abortions” receives +8 points, marker “no abortions” receives 0 points. In the system “availability of surgery on the uterus”, marker “available operations on the uterus” receives +12 points, marker “no operations on the uterus” receives 0 points. In the system “availability of childbirth”, marker “available childbirth” receives 0 points, marker “no childbirth” receives +5 points. In the system “availability of curettage of uterine cavity with concomitant adenomyosis”, marker “available curettage of uterine cavity with concomitant adenomyosis” receives 0 points, marker, “available curettage of uterine cavity without concomitant adenomyosis” receives +10 points. In the system “availability of thyroid disease in women in combination with endometrial hyperplasia”, marker “availability of thyroid disease in women in combination with endometrial hyperplasia” receives 0 points, marker “availability of thyroid disease in women in combination without endometrial hyperplasia” receives +11 points. In the system “atypically located myoma nodes with an assessment of their blood supply”, marker “atypically located myoma nodes with circulatory disorders in them” receives +8 points, marker “atypically located myoma nodes without circulatory disorders in them” receives 0 points. In the system “ABG level with an assessment of the blood supply to myomatous nodes”, marker “ABG level is less than 0.017 g/l and available blood supply disorder in the nodes” receives +15 points, and marker “ABG level is less than 0.017 g/l and absence of blood supply disorders in the nodes” receives 0 points. In the system “level of IL-6 with an assessment of the blood supply to the nodes”, marker “level of IL-6 is more than 3.9 pg/ml and available disorder of blood supply to myomatous nodes” receives +21 points, marker “level of IL-6 is more than 3.9 pg/ml and absence of disorders of blood supply to myomatous nodes” receives 0 points. Obtained points are summed up. If the value of the sum of screening points is more than +20, the proliferating uterus myoma is predicted. At +20 or less, simple uterine myoma is predicted.

EFFECT: method allows to increase the efficiency of non-invasive determination of proliferating and simple uterine fibroids, predict the course of the pathological process and select pathogenetically substantiated methods of treatment through the use of a large amount of clinical and anamnestic data.

1 cl, 2 tbl, 3 ex